Comparative Pharmacology
Head-to-head clinical analysis: ITOVEBI versus OFLOXACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ITOVEBI versus OFLOXACIN.
ITOVEBI vs OFLOXACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ITOVEBI is a monoclonal antibody that inhibits the interaction of programmed cell death protein 1 (PD-1) with its ligands PD-L1 and PD-L2, thereby enhancing T-cell-mediated antitumor immune responses.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
12.5 mg orally once daily
400 mg orally or intravenously every 12 hours for 7-14 days; for uncomplicated gonorrhea, 400 mg as a single oral dose.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours in patients with normal renal function, allowing for once-daily dosing. Half-life is prolonged in renal impairment.
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateOfloxacin + Digoxin
"Ofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateLevofloxacin + Digoxin
"Levofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life is 4-8 hours in adults with normal renal function; prolonged to 20-50 hours in severe renal impairment (CrCl <20 mL/min).
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with biliary/fecal elimination contributing about 30%. The remaining 10% is metabolized.
Approximately 70-90% of an oral dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 4-8% is excreted in feces as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic